-
(单词翻译:双击或拖选)
Medicare considers covering expensive Alzheimer's drug for those in clinical trials
Under a proposal announced Tuesday, Medicare would cover the expensive and controversial Alzheimer's drug Aduhelm — but only for those participating in clinical trials.
RACHEL MARTIN, HOST:
The nation's Medicare program for older Americans has announced a plan to limit coverage2 of a costly3 and controversial new drug for Alzheimer's disease. NPR's Jon Hamilton reports that the plan would require Alzheimer's patients to enroll4 in an approved study of the drug if they want Medicare to pay for it.
JON HAMILTON, BYLINE5: The proposed plan would apply to all drugs that remove a toxic6 substance called amyloid from the brain. Right now there is only one - a drug called aducanumab. It received conditional7 approval from the Food and Drug Administration back in June. Since then, it's been unclear whether Medicare would cover the drug, which may or may not slow the loss of memory and thinking. On Tuesday, the Centers for Medicare and Medicaid Services proposed strict limits on coverage. Dr. Lee Fleisher, the agency's chief medical officer, explained the rationale.
LEE FLEISHER: While there may be the potential for promise with this treatment, there is also the potential for serious harm to patients.
HAMILTON: Side effects often include bleeding or swelling8 in the brain, so the proposal would limit coverage to patients in approved clinical trials. Fleisher says that would allow Medicare to monitor side effects and see whether aducanumab actually provides a benefit. It would also ensure that only people in the earliest stages of Alzheimer's receive the drug, which costs $28,000 a year. The proposal drew sharp criticism from groups including the Alzheimer's Association, which had pushed for more expansive coverage. Robert Egge, the group's chief public policy officer, says patients should not have to join a research study to get the drug.
ROBERT EGGE: It's very important that they're able to meet with their medical providers and figure out if it's the right treatment for them, and if they decide it is, they should have access to it.
HAMILTON: The association says the decision also discriminates9 against Black and Hispanic patients, who are more likely to develop Alzheimer's but less likely to take part in clinical trials. But Sean Dickson of the West Health Policy Center says limiting coverage for aducanumab is appropriate until studies show whether the drug can truly slow the progress of Alzheimer's.
SEAN DICKSON: It's not something that we as taxpayers10 should be paying for if it's not actually going to help people.
HAMILTON: Medicare officials plan to make a final decision about coverage in April.
Jon Hamilton, NPR News.
1 transcript | |
n.抄本,誊本,副本,肄业证书 | |
参考例句: |
|
|
2 coverage | |
n.报导,保险范围,保险额,范围,覆盖 | |
参考例句: |
|
|
3 costly | |
adj.昂贵的,价值高的,豪华的 | |
参考例句: |
|
|
4 enroll | |
v.招收;登记;入学;参军;成为会员(英)enrol | |
参考例句: |
|
|
5 byline | |
n.署名;v.署名 | |
参考例句: |
|
|
6 toxic | |
adj.有毒的,因中毒引起的 | |
参考例句: |
|
|
7 conditional | |
adj.条件的,带有条件的 | |
参考例句: |
|
|
8 swelling | |
n.肿胀 | |
参考例句: |
|
|
9 discriminates | |
分别,辨别,区分( discriminate的第三人称单数 ); 歧视,有差别地对待 | |
参考例句: |
|
|
10 taxpayers | |
纳税人,纳税的机构( taxpayer的名词复数 ) | |
参考例句: |
|
|